We announced that we have concluded exploratory talks with the @EU_Commission for a proposed supply of 200 million doses of #COVID19 #vaccine candidate #BNT162 to #EU member states with an option to purchase additional 100 million doses. https://t.co/g5kjUyHc1f pic.twitter.com/skpCFJu60F
— BioNTech SE (@BioNTech_Group) September 9, 2020
Today and every day, we put #science first. We are committed to the safety & efficacy of #vaccines & testing potential vaccines for #COVID19 in accordance with high ethical standards & sound scientific principles. #WeStandWithScience. @Novavax, we encourage you to stand with us https://t.co/prlsueQRfH pic.twitter.com/yhZezySTzq
— BioNTech SE (@BioNTech_Group) September 8, 2020
We just shared new key data from our U.S. Phase 1 trial for our lead vaccine candidate against #COVID19#BNT162b2. Our global Ph3 study in up to 30k participants is actively enrolling. Up to date, we have dosed more than 11,000 participants! https://t.co/z9Z7vwJ7st pic.twitter.com/zjOuYcc8sr
— BioNTech SE (@BioNTech_Group) August 21, 2020
Today, we provided an update on our corporate progress and reported financial results for Q2. We made significant progress toward our goal of advancing our #oncology programs and toward bringing a #COVID19 vaccine to market as quickly as possible. https://t.co/ARmwdvrkca pic.twitter.com/XuwixADlqf
— BioNTech SE (@BioNTech_Group) August 11, 2020
We announced an agreement with #Japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #TokyoOlympics. https://t.co/YUmpvqELru pic.twitter.com/VcubAIgTvd
— BioNTech SE (@BioNTech_Group) July 31, 2020
We announced the start of a global Phase 2/3 safety and efficacy study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from our #BNT162 mRNA-based vaccine program conducted together with our partner @Pfizer. https://t.co/TSBaTLr8TK pic.twitter.com/MrL0J7baR2
— BioNTech SE (@BioNTech_Group) July 28, 2020
We announced an agreement with the #UK for 30m doses of our mRNA-based vaccine candidate against #COVID19. We currently expect to manufacture up to 100m doses by the end of 2020 & potentially more than 1.3bn doses by the end of 2021 together with @pfizer. https://t.co/ce5YLGNul2 pic.twitter.com/fCe34houbI
— BioNTech SE (@BioNTech_Group) July 20, 2020
We are proud to have received Fast Track designation from the U.S. FDA for two of our four investigational vaccine candidates from the #BNT162 mRNA-based vaccine program. They are being developed to help protect against #COVID19. https://t.co/NHcWj8wJqg pic.twitter.com/jHo6DxCSyc
— BioNTech SE (@BioNTech_Group) July 13, 2020
Today, we announced early positive data from the #US and as part of our global #COVID19 development program in collaboration with @pfizer. Find the key facts in our press release: https://t.co/YyvaOE49eP pic.twitter.com/9XemM0jJ4C
— BioNTech SE (@BioNTech_Group) July 1, 2020
Listen in to @CNN's @fpleitgenCNN discussing the progress of our global #COVID19 development program with our CEO Ugur Sahin. Thanks for having us! https://t.co/OqRN4j7vYM
— BioNTech SE (@BioNTech_Group) May 6, 2020
What a special moment! The first participant was dosed with our #COVID-19 vaccine candidate BNT162. Furthermore, the first cohort of 12 study participants in our Phase 1/2 trial has been successfully completed. pic.twitter.com/T261AmrfS4
— BioNTech SE (@BioNTech_Group) April 29, 2020
Today, the German regulatory authority, the @PEI_Germany, approved the Phase 1/2 clinical trial for our #vaccine program to prevent #COVID19 infection. More about the milestone in our global development program in collaboration with @pfizer & Fosun Pharma: https://t.co/nXZe90dbNe pic.twitter.com/TibuNp5yJv
— BioNTech SE (@BioNTech_Group) April 22, 2020
We are excited to have announced additional details on our collaboration with @pfizer to rapidly advance multiple mRNA-based COVID-19 vaccine candidates into clinical testing and ramp-up production capacities. https://t.co/fyp0S1T2US pic.twitter.com/AJbPFuJe0s
— BioNTech SE (@BioNTech_Group) April 9, 2020
Today, we announced our full year 2019 financial results. Last year has been transformational for us. In 2020, we plan to continue building a 21st century company to develop pioneering therapeutics for #cancer & other diseases with an unmet patient need. https://t.co/2h5kB3Sz4e pic.twitter.com/rBWzq70LIY
— BioNTech SE (@BioNTech_Group) March 31, 2020
If you ever wondered what it is like to work with Ugur Sahin on the development of a #COVIDー19 vaccine, the @FT provides insights. https://t.co/XWJsn07rPF
— BioNTech SE (@BioNTech_Group) March 23, 2020
Watch our Chief Business and Chief Commercial Office Sean Marett discuss BioNTech’s vaccine program for the prevention of Covid-19 infection and our global development program on @CNBC. https://t.co/BnrgzwCeug
— BioNTech SE (@BioNTech_Group) March 17, 2020
Today, we announced that we have agreed to a letter of intent regarding the co-development & distribution (excl. China) of a potential mRNA-based coronavirus vaccine aimed at preventing #COVID19 infection with @pfizer. Read our Press Release: https://t.co/tGZ2sYTb8U pic.twitter.com/yJoZegYut1
— BioNTech SE (@BioNTech_Group) March 17, 2020
We are excited to announce that we have entered into a definitive #merger #agreement under which we will acquire @neon_tx to strengthen our #global #leadership position in T #celltherapies. Read more here: https://t.co/ciK7LsP3JA #immunooncology #cancerimmunotherapy #oncology pic.twitter.com/riQEgBA2u2
— BioNTech SE (@BioNTech_Group) January 16, 2020
Interested in European biotech companies? We are happy to be named one of the 20 European #biotech companies to follow this year. @Labiotech_eu consulted with experts to identify the companies across all areas of biotech. #2020 Check out the entire list: https://t.co/q1oemQYWpy
— BioNTech SE (@BioNTech_Group) January 7, 2020
Preclinical PoC data on our first solid #tumor #CART program BNT211 were published in the current issue of @sciencemagazine. Read the full paper on how we aim to overcome the existing hurdles and create an efficient approach with our CARVac technology here https://t.co/6ho27ZrzX0 pic.twitter.com/f2sDmhr6mC
— BioNTech SE (@BioNTech_Group) January 2, 2020
We announced a €50M financing from @EIB to advance R&D, market access and manufacturing development of our most advanced treatments under development. #junkerplan #Europe #innovation pic.twitter.com/l2peDRfOE2
— BioNTech SE (@BioNTech_Group) December 18, 2019
We are on top in @GENbio’s ranking of the 10 best immuno-oncology start-ups of 2019. Thanks @AlexWestchester for including us! https://t.co/4k4ZuiFwXK
— BioNTech SE (@BioNTech_Group) December 5, 2019
Read more about our #CMO Özlem Türeci in @endpts special report on 20 extraordinary #women in #biopharma. Özlem is one of many women at #BioNTech who support our vision. https://t.co/ZVTARdtleD
— BioNTech SE (@BioNTech_Group) November 20, 2019
Proud to be named company of the year at this year’s @LSXLeaders #lifestarawards, big thanks to the BioNTech family! https://t.co/mIrF1Yq472
— BioNTech SE (@BioNTech_Group) November 20, 2019
We are proud to announce that BioNTech is now officially @Nasdaq. This is an important step on our journey to individualize cancer medicine globally. #BioNTechIPO $BNTX pic.twitter.com/2ACCqVnfCP
— BioNTech SE (@BioNTech_Group) October 11, 2019
It’s official! First day of trading begins for $BNTX on Thursday, October 10th at 9:30am ET (3:30pm CET) #BioNTechIPO https://t.co/KM7esGYRP8
— BioNTech SE (@BioNTech_Group) October 10, 2019
We are excited to announce the closing of a $325M #SeriesB round, one of the largest private #financing events for a #European #biotech company to advance our #individualized #cancer medicine pipeline. #DigitalTransformation #AI See full press release here:https://t.co/968cll2GPU pic.twitter.com/5Fvspp4Wyv
— BioNTech SE (@BioNTech_Group) July 9, 2019
BioNTech CBO/CCO, Sean Marett, is featured on our collaborator's @Roche website discussing advances in the #cancer-immunity cycle. Click here to read about how together we are individualizing #cancercare with innovative vaccines & technology: https://t.co/4401rw57WM pic.twitter.com/sq2lDK1fyH
— BioNTech SE (@BioNTech_Group) June 24, 2019
We are delighted to announce the initiation of the #FirstinHuman Phase I/IIa study with #bispecific #antibody DuoBody®-PD-L1x4-1BB in #solidtumors. It is the 1st candidate from our collaboration with @Genmab to enter the clinic after only 4 years. https://t.co/gkx3IuycUL pic.twitter.com/inhNc15R00
— BioNTech SE (@BioNTech_Group) June 17, 2019
Today we announced the acquisition of MabVax Therapeutics’ #antibody assets to expand our portfolio. See here for the full announcement: https://t.co/3I6CemMuGp pic.twitter.com/gzn8SOk9Sk
— BioNTech SE (@BioNTech_Group) May 8, 2019
Thank you at @techreview @BillGates for including us in the 10 breakthrough technologies of 2019! We are committed to bringing individualized cancer immunotherapies into clinical application. More on our approach here: https://t.co/zfLO4mj9Z8 https://t.co/eBRHqFLcpv
— BioNTech SE (@BioNTech_Group) February 28, 2019
We are delighted to announce that our CEO, Ugur Sahin was awarded the German Cancer Award 2019 by @DKG_Berlin, one of the most prestigious awards in #cancer medicine in Germany. Read the full announcement here:https://t.co/aDuyZiZa6Z pic.twitter.com/z05JF9iGVG
— BioNTech SE (@BioNTech_Group) February 28, 2019
Today we announced we are undergoing a corporate transition from AG to SE. The transition will enable greater flexibility to operate globally and engage in fund-raising transactions & partnerships with other international corporations. https://t.co/MI6gxcHvox pic.twitter.com/SPFafucdwF
— BioNTech SE (@BioNTech_Group) January 4, 2019
Today we announced that we have extended our research collaboration w/ @sanofi & that Sanofi is investing $91.5m (€80m) in equity. This partnership will support the advancement of mRNA-based cancer immunotherapy into clinical testing against multiple solid tumors. pic.twitter.com/OgzMSr3Qyj
— BioNTech SE (@BioNTech_Group) January 4, 2019
.@nature has published trial data demonstrating proof-of-concept of the @GAPVAC approach against glioblastoma. The results of this highly personalized method provide promise for the future of immunotherapy: https://t.co/DLPw3Kw6Ri #GAPVAC #cancer #vaccine
— BioNTech SE (@BioNTech_Group) December 19, 2018
Get an update on BioNTech from our CBO/CCO, Sean Marett who had the opportunity to be interviewed by @ScripMikeWard during #BIOEurope2018. Sean gave more background on BioNTech’s move into #infectiousdiseases & recent related deals w/ @pfizer & University of Pennsylvania https://t.co/a64LvMdlsa
— BioNTech SE (@BioNTech_Group) December 7, 2018
We are pleased to have been included in @Labiotech_eu’s overview on ‘How to Turn Your Biotech Startup into a Successful Company.’ See the full article here: https://t.co/y9HCBWxDlM pic.twitter.com/ydVHUIFOBg
— BioNTech SE (@BioNTech_Group) December 6, 2018
Sean Marett, our CBO/CCO has been invited to be a panelist on the RNA panel titled, ‘The year of RNA and the start of a new era.’ The panel is 1 out of 6 at the 2019 #BiotechShowcase that is highlighted as a #therapeutic area garnering attention for investment in 2019 https://t.co/265s7eVqT7
— BioNTech SE (@BioNTech_Group) December 5, 2018
Pfizer may be first to reveal late-stage results from its Covid vaccine trials with partner BioNTech. And if history is any guide, the shares may head lower no matter what the data show. https://t.co/SJdneKtWrs
— Bloomberg (@business) September 14, 2020
#jpmorgan analyst Cory Kasimov focused in on mRNA-1273 from Moderna $MRNA & BNT162 from BioNTech $BNTX, laying odds on which of the two has the best chance of success — and which might win FDA approval first. #investments #vaccines #stockmarket #COVID_19 https://t.co/KKNOHLJziI
— Corona Stocks (@CoronaStocks) September 14, 2020
.@AstraZeneca Phase III trial was resumed. .@BioNTech_Group and .@pfizer are seeking approval to expand their Phase II/III trial to 44,000 participants. Learn more: https://t.co/nXFDIZhPiP #covid19 pic.twitter.com/nZbmupy8hD
— Genetic Engineering & Biotechnology News (@GENbio) September 14, 2020
COVID News: AstraZeneca's Phase III trial was resumed after receiving confirmation from the U.K.’s Medicines Health Regulatory Authority. BioNTech and Pfizer are seeking approval to expand their Phase II/III trial to about 44,000 participants. Learn more: https://t.co/9nakPM0SZ1 pic.twitter.com/POnK6VCuT6
— Genetic Engineering & Biotechnology News (@GENbio) September 14, 2020
Preclinical Data Supports Efficacy for Pfizer, BioNTech Phase II/III COVID-19 Vaccine https://t.co/M8lGxMn4aL pic.twitter.com/W9Vy4QsKUW
— VCapital (@VCapital_invest) September 15, 2020
The timeline for an approved coronavirus vaccine has been muddied by a series of big stories in the last few weeks, making it hard to tell if there truly could be a light at the end of… #astrazeneca #BioNtech #Pfizer https://t.co/UJbFvNTAKb pic.twitter.com/5ieTeOTuCs
— Wall Street Wire (@wallstwire) September 14, 2020
Navajo Nation officials said they will participate in the Pfizer-BioNTech COVID-19 vaccine trials amid a steady decline in coronavirus cases.https://t.co/mxMVMFzTyb
— KJZZ Phoenix (@kjzzphoenix) September 15, 2020
Navajo Nation to participate in Pfizer-BioNTech COVID-19 vaccine trial on patient-volunteer basis pic.twitter.com/HlaX7Hi4eL
— Navajo Nation President Jonathan Nez (@NNPrezNez) September 11, 2020
Pfizer, Biontech Say #COVID-19 Vaccine Might Be Ready by End of October https://t.co/H3lAZHRHjE #usdmlifesciences
— USDM Life Sciences (@USDMLifeScience) September 14, 2020
Pfizer, BioNTech Say COVID-19 Vaccine Might Be Ready by End of October#biospace #lifesciences #biotechnology #pharmaceuticals #clinicaltrials #COVID-19 #coronavirus #pandemic #COVID19 #treatment #vaccinehttps://t.co/jcaebs4iaH
— BioSpace (@biospace) September 14, 2020
@pfizer and BioNTech are moving to enlarge the Phase 3 trial of their #Covid-19 vaccine by 50%, which could allow the companies to collect more safety and efficacy data and to increase the diversity of the study’s participants.https://t.co/ztpC5lrH2w pic.twitter.com/3SNPfdjEjh
— Georgia Bio (@Georgia_Bio) September 14, 2020
COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study#HIV #ResearchMatters #BioTech #Virologyhttps://t.co/FRm2dwW9U4 via @eMPR
— HIV & AIDS Updates U=U (@HIVAIDSupdates) September 14, 2020
Upping the phase 3 investigational #vaccine trial size to 44,000 participants will also allow for the enrollment of new populations.#Pfizer #BioNTech #COVID19 #SARSCoV2 https://t.co/5Y5is1RxDA
— Contagion (@Contagion_Live) September 14, 2020
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial #pharmatopnews https://t.co/J6queolOFy
— Pharma Top News (@PharmaTopNews1) September 14, 2020
14September: @AstraZeneca, @UniofOxford Resume Phase III Trial; @pfizer, @BioNTech_Group Eye 14,000 More Participants. Read more about the companies' Phase III #COVID19 trials in @GENbio — https://t.co/2b3hwHkidN
— Alex Philippidis (@AlexWestchester) September 14, 2020
American pharmaceutical company Pfizer and its German partner, BioNTech, have proposed expanding Phase 3 clinical trials for a coronavirus vaccine to include 44,000 participants and more diverse patient populations, including people as young as 16. https://t.co/VVpqLS8Ivg
— CNN (@CNN) September 14, 2020
Thousands of more volunteers will soon become part of Pfizer and BioNTech's expanded phase 3 trials of a potential COVID-19 vaccine.
Here's @Jette680News with this morning's Health Report:https://t.co/o1z8HukPNT
— 680 NEWS Toronto (@680NEWS) September 14, 2020
#CoronavirusVaccine #Covid19protection
Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October https://t.co/u11WPrRY1x— EastMojo (@EastMojo) September 14, 2020
Fosun Pharma has partnered with American pharmaceutical giant Pfizer and the German vaccine maker BioNTech to co-develop an mRNA vaccine that is currently in late-stage trials. Dr. Aimin Hui interviewed on a virtual call for Fortune’s Global Tech Forum. https://t.co/nyRS3zbqvu
— Fosun (@Fosun_Intl) September 14, 2020
Pfizer and BioNTech also said they now want to boost their phase 2/3 trial for one of their five mRNA vaccines, BNT162b2, from around 30,000 to 44,000. https://t.co/nzHdI4YW4V
— FierceBiotech (@FierceBiotech) September 14, 2020
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi have signed a joint pledge https://t.co/MuVvhDvMKV
— FierceBiotech (@FierceBiotech) September 8, 2020
Coronavirus vaccine by Pfizer-BioNTech could be available by end of 2020, claims top official https://t.co/pVEPyB95JT
— Everyday Taxes (@EverydayTaxes) September 14, 2020
Hey @pfizer @AstraZeneca @BioNTech_Group @GSK Researchers said that missing from the joint statement was a promise to share more critical details about their research with the public and the scientific community. https://t.co/MnIKGgHurw
— Everyday Activism (@5MinuteActivism) September 14, 2020
BioNTech assigns Dermapharm to produce its COVID-19 vaccine by Eva Wesley https://t.co/medxdiPes1
— Born2Invest (@born2invest) September 14, 2020
Navajo Nation officials said they will participate in the Pfizer-BioNTech COVID-19 vaccine trials amid a steady decline in coronavirus cases.https://t.co/mxMVMFzTyb
— KJZZ Phoenix (@kjzzphoenix) September 14, 2020
.@pfizer and @BioNTech_Group submit proposal to @US_FDA to expand #COVID19 #vaccine trial https://t.co/WXCanaIQWm | #pharma #pharmanews #IndiaIncfightsCovid19
— ExpPharma (@ExpPharma) September 13, 2020
Pfizer and BioNTech are moving to enlarge the Phase 3 trial of their Covid-19 vaccine by 50%. https://t.co/lbc4unoHxN
— STAT (@statnews) September 13, 2020
Pfizer/BioNTech are expanding the size of their phase 3 #covid19 vaccine trial to 44k from 30k to increase diversity and include people with other viral diseases.
Still expect efficacy data potentially by the end of October. pic.twitter.com/ZgAMQGYemh
— Meg Tirrell (@megtirrell) September 12, 2020
@pfizer @BioNTech_Group propose @US_FDA to increase #COVID19 #vaccine #Clinicaltrial fr 30K participants to 44K so to increase trial population #Diversity include adolescents 16 yrs of age, patients of #HIV #Hepatitis C or B @statnews @matthewherper https://t.co/1dDCyjfAAX pic.twitter.com/Te3AS72R7R
— FlatBio (@Flat_Bio) September 12, 2020
Pfizer & BioNTech are expanding the size of their US Phase 3 #Covid19 vaccine trial. Going to test the vaccine in 44,000 people, up from 30,000, @matthewherper reports. Will lower enrollment age to 16 & include people with stable HIV. https://t.co/NpoKLfUikV
— Helen Branswell (@HelenBranswell) September 12, 2020
Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteers https://t.co/r205UJdtKx pic.twitter.com/0vB92i4cy9
— Reuters (@Reuters) September 12, 2020
@Rijksoverheid announce conclusion of talks with @BioNTech_Group & @pfizer on sixth possible #COVID19 #vaccine.
Head to our Facebook page for full article: https://t.co/GQTgi2zy6W pic.twitter.com/3bmiZmsOsA— News in English – RTV Maastricht (@newsmaastricht) September 10, 2020
Nine #vaccine developers pledged to make safety and well-being top priority in developing #COVID19 vaccines; One halts trials for safety review. https://t.co/fUk2LGsamf @AstraZenecaUS @BioNTech_Group @GSKUS @JNJNews @Merck @pfizer @SanofiUS #COVID19Vaccine
— InfectiousDiseaseSE (@IDSE_Online) September 9, 2020
With the conclusion of the talks with @BioNTech_Group, we now have made significant steps ahead with 6 major vaccine companies.
That is 6 times more chances to provide safe and effective #COVID19 vaccines for Europeans – and the rest of the world.https://t.co/lqOqUrG0u1
— Ursula von der Leyen (@vonderleyen) September 9, 2020
EU signs deal with BioNTech-Pfizer for 200 million doses of COVID-19 vaccine https://t.co/arZApLu34n
— Republic (@republic) September 9, 2020
Five things for pharma marketers to know: Wednesday, September 9, 2020 | @alisonkanski via @MMMnews #COVID19 #DrFauci #Vaccine@moderna_tx @pfizer @BioNTech_Group @AstraZenecaUS @uberhealth @US_FDA https://t.co/ISdeveiRsd
— DMD America, Inc (@AnalySource) September 9, 2020
In a historic pledge, #JNJ, along with @Pfizer, @AstraZeneca, @Sanofi, @Moderna_tx, @BioNTech_Group, @GSK, @Merck and @Novavax have outlined a united commitment to upholding the integrity of the scientific process as we develop a #COVID19 vaccine. #WeStandWithScience
— Johnson & Johnson (@JNJNews) September 10, 2020
Shares of BionTech and CureVac gain 3% as AstraZeneca Vaccine tests face delay after patient gets ill. AstraZeneca does not use the mRNA technology like BionTech or CureVac. pic.twitter.com/8TTbAtwJwN
— Holger Zschaepitz (@Schuldensuehner) September 9, 2020
In a historic pledge, #JNJ, @Pfizer, @AstraZeneca, @Sanofi, @Moderna_tx, @BioNTech_Group, @GSK, @Merck & @Novavax have outlined a united commitment to upholding the integrity of the scientific process as we develop a #COVID19 vaccine. #WeStandWithScience pic.twitter.com/muF9nnAaLW
— Janssen EMEA (@JanssenEMEA) September 9, 2020
We are proud to participate in this pledge to uphold the integrity of the scientific process in the research and development of a #COVID19 vaccine. #WeStandWithScience, and @BioNTech_Group, we invite you to stand with us. https://t.co/O1wDca3KoU pic.twitter.com/34Y2VMRTrS
— Moderna (@moderna_tx) September 8, 2020
Alongside @pfizer, @GSK, @JNJNews, @AstraZeneca, @Merck, @moderna_tx, @BioNTech_Group & @Novavax we’ve announced a historic pledge to uphold the integrity of the scientific process for developing the first potential #COVID19 vaccines: https://t.co/YqN3QMwiJU #WeStandWithScience pic.twitter.com/T5UgGcRnnE
— Sanofi US (@SanofiUS) September 8, 2020
#WeStandWithScience @Pfizer @JNJNews @AstraZeneca @Sanofi @Moderna_tx @BioNTech_Group @GSK @Merck pic.twitter.com/9uzjqrCtPr
— Novavax (@Novavax) September 8, 2020
We invite and encourage the public and the biopharma and life science community to join us as #WeStandWithScience @Pfizer @JNJNews @AstraZeneca @Sanofi @Moderna_tx @BioNTech_Group @GSK @Merck #vaccines #COVID19 https://t.co/mniynbtBzx pic.twitter.com/QgtQAFoh7J
— Novavax (@Novavax) September 8, 2020
FYI via @NephronResearch re: logistics/channel issues for #COVID19 #vaccines@pfizer / @BioNTech_Group / @Merck = ultra-low temp (-70C) = #hospitals & other medical settings@moderna_tx = freezer temp (-20C) = physician offices & #pharmacies (but colder than std refrigeration) pic.twitter.com/lLxLnpAjKe
— Adam J. Fein (@DrugChannels) September 15, 2020
“In the interest of public health, we pledge to always make the safety & well-being of vaccinated individuals our top priority,” – executives from: AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer & Sanofi.https://t.co/HeCXNpqiob
— Shawnté #BLM James, MD 😷 (@ShawnteJamesMD) September 8, 2020
9 Pharma Majors that are developing #CoronaVaccine have signed a Pledge that they will not rush the vaccine, but wait to make sure it is completely safe and effective
They are Pfizer, Moderna, AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Novavax, and Sanofi
— Ramesh Bala (@rameshlaus) September 8, 2020